Financial De-Escalation in T1 Breast Cancers With the Low Magee Equation: An Experience From A Single Institution Without Genomic Testing
This study suggests that omitting the Oncotype Dx<sup>®</sup> assay may be feasible in postmenopausal women with early breast cancer and an ME2 score ≤18. Using comparable tools, such as ME2, may reduce financial toxicity in this population and overall costs to the system. Larger study recommended.
Authors
- Faith Seltun (ORCID: https://orcid.org/0009-0004-8804-6990)
- Caroline E. Lippe
- Yijin Wert
- Kit Lu
- Atilla Soran
- Katherine Barton
- Manpreet Sandhu
- Berkay Demirors
Institutions
- Main Line Health (US)
- Bryn Mawr Hospital (US)
- Magee-Womens Hospital (US)
- University of Pittsburgh Medical Center (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- European Journal of Breast Health
- Published
- 2025-12-25
- DOI
- https://doi.org/10.4274/ejbh.galenos.2025.2025-6-10
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00